Tnp 351 | CAS#125991-51-7 | antifolate

MedKoo Cat#: 597228 | Name: Tnp 351

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tnp 351 is a novel antifolate being evaluated for chemotherapy of lung cancer.

Chemical Structure

Tnp 351

CAS#125991-51-7

Theoretical Analysis

MedKoo Cat#: 597228

Name: Tnp 351

CAS#: 125991-51-7

Chemical Formula: C21H24N6O5

Exact Mass: 440.1808

Molecular Weight: 440.46

Elemental Analysis: C, 57.27; H, 5.49; N, 19.08; O, 18.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Tnp 351; Tnp-351; Tnp351;

IUPAC/Chemical Name

(4-(3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)benzoyl)-L-glutamic acid

InChi Key

WLGCEMWNUHSIIS-AWEZNQCLSA-N

InChi Code

InChI=1S/C21H24N6O5/c22-17-16-13(10-24-18(16)27-21(23)26-17)3-1-2-11-4-6-12(7-5-11)19(30)25-14(20(31)32)8-9-15(28)29/h4-7,10,14H,1-3,8-9H2,(H,25,30)(H,28,29)(H,31,32)(H5,22,23,24,26,27)/t14-/m0/s1

SMILES Code

O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(CCCC2=CN=C3NC(N)=NC(N)=C32)C=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 440.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Taylor EC, Liu B. A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine anticancer agents: Alimta (LY231514, MTA), homo-Alimta, TNP-351, and some aryl 5-substituted pyrrolo[2,3-d]pyrimidines. J Org Chem. 2003 Dec 26;68(26):9938-47. PubMed PMID: 14682686. 2: Itoh F, Yoshioka Y, Yukishige K, Yoshida S, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs. Chem Pharm Bull (Tokyo). 2000 Sep;48(9):1270-80. PubMed PMID: 10993224. 3: Matsuo K, Kiura K, Ueoka H, Tabata M, Shibayama T, Matsumura T, Takigawa N, Hiraki S, Harada M. Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line. Acta Med Okayama. 1997 Jun;51(3):121-7. Erratum in: Acta Med Okayama 1997 Aug;51(4):237. PubMed PMID: 9227790. 4: Taylor EC, Mao Z. A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974. PubMed PMID: 11667765. 5: Itoh F, Yoshioka Y, Yukishige K, Yoshida S, Wajima M, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs. Chem Pharm Bull (Tokyo). 1996 Aug;44(8):1498-509. PubMed PMID: 8795269. 6: Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T, et al. [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Gan To Kagaku Ryoho. 1995 Feb;22(2):259-71. Japanese. PubMed PMID: 7857102. 7: Aso K, Hitaka T, Yukishige K, Ootsu K, Akimoto H. Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):256-61. PubMed PMID: 7728932. 8: Itoh F, Yukishige K, Wajima M, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):230-5. PubMed PMID: 7728929. 9: Itoh F, Russello O, Akimoto H, Beardsley GP. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis. Cancer Chemother Pharmacol. 1994;34(4):273-9. PubMed PMID: 8033293. 10: Tsukagoshi S. [Development of antimetabolites, II]. Gan To Kagaku Ryoho. 1993 Jan;20(1):19-26. Review. Japanese. PubMed PMID: 8422184. 11: Yoshimura A. [New analogues of methotrexate]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2133-9. Review. Japanese. PubMed PMID: 1444480.